Antheia, a Menlo Parck CA-based synthetic biology company, raised $73M in Series B funding.
The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire.
The company intends to use the funds to expand its pipeline and scale production in global markets.
Led by Dr. Christina Smolke, cofounder and CEO, Antheia is a synthetic biology company enabling next-generation plant-inspired medicines through a novel whole-cell engineering approach to reconstruct complex molecules in yeast. The funds will support the company to bring its first pharmaceutical compound to market and scale up the production of a number of active pharmaceutical ingredients (APIs) and key starting materials (KSMs).
The platform can be applied to a wide range of pharmaceuticals that typically use plant-derived molecules, including analgesics, antitussives, chemotherapeutics, and neurotransmitter inhibitors. Additionally, it opens up the potential to develop novel drugs in a chemical space, making it possible to address biological targets that are currently considered “undruggable.”